Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs

Reuters

06/20

Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs

Evolent Health Inc. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH14625) on June 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544126691"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544126691\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544126691?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544126691","market":"us","top_or_hot":-1,"title":"Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVH\">Evolent Health Inc</a>. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH14625) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-20 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVH\">Evolent Health Inc</a>. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH14625) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2361044949.HKD","symbol_name":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL7NpxMR:1","article_id":"2544126691","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544126691","pubTimestamp":1750415423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evolent Health Inc.  has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","ARES":"Ares Management L.P.","BK4135":"资产管理与托管银行","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0971096721.USD":"富达环球金融服务 A","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","EVH":"Evolent Health Inc","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","BK4167":"医疗保健技术"},"translate_title":"由于肿瘤费用低于预期，Evolent Health重申第二季度和全年调整后EBITDA指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARES":0.9,"EVH":0.9},"content_text":"Evolent Health Reiterates Q2 and Full Year Adjusted EBITDA Guidance Amid Lower-than-Expected Oncology Costs\n    \n\nEvolent Health Inc. (NYSE: EVH) has reiterated its guidance for the second quarter and full year 2025, projecting Adjusted EBITDA of $33 million to $40 million for Q2 and $135 million to $165 million for the full year. The company noted that it is experiencing oncology cost trends below expectations, which has contributed to its confidence in meeting or exceeding these forecasts. John Johnson, Evolent's Chief Financial Officer, expressed optimism about achieving the upper end of the Q2 Adjusted EBITDA range if current trends continue through June. Additionally, Evolent Health announced a significant increase in its forecast for new revenue bookings heading into 2026, driven by accelerated business development activities. To support this growth, the company secured a Commitment Letter with Ares Management Credit funds, providing an option for additional non-dilutive capital to manage its 2025 Convertible Notes and support its expanding organic growth pipeline.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH14625) on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}